Liou B.-H.HSIN-YUN SUNYang C.-J.Syue L.-S.Lee Y.-L.Tang H.-J.Tsai H.-C.Lin C.-Y.Chen T.-C.Lee C.-Y.Huang S.-H.Liu C.-W.Lu P.-L.Lin S.-P.Wang N.-C.ARISTINE CHENGKo W.-C.Cheng S.-H.CHIEN-CHING HUNGthe Taiwan HIV Study Group2021-08-162021-08-1620212193-8229https://www.scopus.com/inward/record.uri?eid=2-s2.0-85103069272&doi=10.1007%2fs40121-021-00424-8&partnerID=40&md5=736e4bd066b5affbd28a7e051a966945https://scholars.lib.ntu.edu.tw/handle/123456789/578076Introduction: While coformulated ledipasvir (90?mg)/sofosbuvir (400?mg) (LDV/SOF) is approved for the treatment of hepatitis C virus (HCV) genotype 2 (GT2) infection in Taiwan, Japan, and New Zealand, data regarding its use for HIV (Human Immunodeficiency Virus)-positive patients infected with HCV GT2 are sparse. We aimed to assess the effectiveness and tolerability of LDV/SOF for HIV-positive patients with HCV GT2 coinfection. Methods: From January 2019 to July 2020, consecutive HIV-positive Taiwanese patients infected with HCV GT2 who received LDV/SOF were retrospectively included for analysis. The effectiveness was determined by sustained virologic response 12?weeks off-therapy (SVR12). Results: Of the 114 patients (mean age, 38.6?years) initiating LDV/SOF during the study period, 0.9% had liver cirrhosis and 4.4% were HCV treatment-experienced. All patients had estimated glomerular filtration rate (eGFR)?>?30?ml/min/1.73?m2 and were receiving antiretroviral therapy with 98.2% having CD4 counts???200 cells/mm3 and 93.9% plasma HIV RNA load?<?50 copies/ml. Antiretrovirals prescribed included tenofovir alafenamide/emtricitabine in 42.1%, tenofovir disoproxil fumarate (TDF)/emtricitabine 18.4%, other nucleoside reverse transcriptase inhibitors (NRTIs) 39.5%, non-NRTIs 12.3%, protease inhibitors 13.2%, and integrase inhibitors 74.6%. All patients had undetectable plasma HCV RNA load at the end of treatment, and 96.5% achieved SVR12 in intention-to-treat analysis. The on-treatment eGFR decline was more pronounced in those receiving TDF-containing antiretroviral therapy (mean change, ??8.33?ml/min/1.73?m2), which was reversible after discontinuation of LDV/SOF. None of the patients interrupted LDV/SOF during the 12-week treatment course. Conclusion: Similar to the response observed among HIV-negative patients, LDV/SOF is effective for HIV-positive patients coinfected with HCV GT2. ? 2021, The Author(s).[SDGs]SDG3alanine aminotransferase; amiodarone; aspartate aminotransferase; entecavir; integrase inhibitor; lamivudine; ledipasvir; phenytoin; proteinase inhibitor; sofosbuvir; acute hepatitis C; adult; antiretroviral therapy; Article; cell cycle arrest; chronic hepatitis B; chronic kidney failure; coinfection; comparative effectiveness; data analysis software; echography; estimated glomerular filtration rate; female; genotype; hemodialysis; Hepatitis B virus; hepatitis C; Hepatitis C virus; human; Human immunodeficiency virus; liver cirrhosis; major clinical study; male; multicenter study; prevalence; retrospective study; viremia; virus load; virus replicationjournal article10.1007/s40121-021-00424-82-s2.0-85103069272